Publication Date
| In 2026 | 0 |
| Since 2025 | 0 |
| Since 2022 (last 5 years) | 0 |
| Since 2017 (last 10 years) | 1 |
| Since 2007 (last 20 years) | 1 |
Descriptor
| Anxiety | 1 |
| Attention Deficit… | 1 |
| Autism | 1 |
| Children | 1 |
| Drug Therapy | 1 |
| Early Adolescents | 1 |
| Experimental Groups | 1 |
| Parent Education | 1 |
| Parents | 1 |
| Pervasive Developmental… | 1 |
| Randomized Controlled Trials | 1 |
| More ▼ | |
Source
| Journal of Autism and… | 1 |
Author
| Aman, Michael G. | 1 |
| Arnold, L. Eugene | 1 |
| Handen, Benjamin L. | 1 |
| Hollway, Jill | 1 |
| Lecavalier, Luc | 1 |
| Pan, Xueliang | 1 |
| Silverman, Laura | 1 |
| Smith, Tristram | 1 |
| Tumuluru, Rameshwari V. | 1 |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
| Adult Education | 1 |
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkLecavalier, Luc; Pan, Xueliang; Smith, Tristram; Handen, Benjamin L.; Arnold, L. Eugene; Silverman, Laura; Tumuluru, Rameshwari V.; Hollway, Jill; Aman, Michael G. – Journal of Autism and Developmental Disorders, 2018
We previously reported a 2 × 2 randomized clinical trial of atomoxetine (ATX) and parent training (PT) for attention deficit hyperactivity disorder (ADHD) symptoms and behavioral noncompliance in 128 children with autism spectrum disorder, ages 5-14 years. Children were randomized to one of four conditions: ATX alone, placebo alone, ATX + PT, or…
Descriptors: Parents, Anxiety, Stress Variables, Pervasive Developmental Disorders
